Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2(V617F)-induced myeloproliferative neoplasms

Janus kinase 2 (JAK2) hyperactivation by JAK2(V617F) mutation leads to myeloproliferative neoplasms (MPNs) and targeting JAK2 could serve as a promising therapeutic strategy for MPNs. Here, we report that Flonoltinib Maleate (FM), a selective JAK2/FLT3 inhibitor, shows high selectivity for JAK2 over...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Mengshi, Yang, Tao, Yang, Linyu, Niu, Lu, Zhu, Jinbing, Zhao, Ailin, Shi, Mingsong, Yuan, Xue, Tang, Minghai, Yang, Jianhong, Pei, Heying, Yang, Zhuang, Chen, Qiang, Ye, Haoyu, Niu, Ting, Chen, Lijuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901636/
https://www.ncbi.nlm.nih.gov/pubmed/35256594
http://dx.doi.org/10.1038/s41408-022-00628-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901636/
https://www.ncbi.nlm.nih.gov/pubmed/35256594
http://dx.doi.org/10.1038/s41408-022-00628-2

Ejemplares similares